Madrid

• A clinical study of patritumab deruxtecan in people with breast cancer Recruiting
  2024-514376-40-00 4 2025-10-15 High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• A research study to evaluate how well etavopivat works in people with sickle cell disease - Hibiscus 2 Recruiting
  2023-509175-16-00 5 2025-10-14 Sickle cell disease
• Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea … Recruiting
  2024-511459-16-00 9 2025-10-14 Histologically confirmed pancreatic adenocarcinoma with liver metastas
• A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre … Recruiting
  2024-512421-92-00 7 2025-10-14 Unresectable, Locally Advanced or Metastatic Cancer
• Clinical trial to evaluate the efficacy and safety of the topical application of Impetine® Gel (mupirocin 20 mg/g) compared with Bactroban® … Recruiting
  2024-517475-20-00 5 2025-10-13 Impetigo
• A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A Recruiting
  2025-520490-38-00 3 2025-10-13 Haemophilia A with or without inhibitors. Proposed indication under de
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG) Recruiting
  2024-520355-25-00 5 2025-10-10 generalized myasthenia gravis
• Reduced Immunosuppression for Older Adult Kidney Transplant Recipients: the RELEASE study. Recruiting
  2025-520535-16-00 6 2025-10-10 End-stage renal disease
• VALIDATION OF THE SENTINEL LYMPH NODE TECHNIQUE IN EARLY-STAGE OVARIAN CANCER (SENTOV II) Recruiting
  2024-520189-67-00 5 2025-10-08 OVARIAN CANCER
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 Lung Cancer
• A Phase 1/1b Study of IAM1363 in HER2 Cancers Recruiting
  2024-519188-17-00 1 2025-10-07 Relapsed/refractory malignancy with documented diagnosis of human epid
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients … Recruiting
  2024-514152-32-00 3 2025-10-06 Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)
• A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting
  2024-515682-34-00 5 2025-10-06 Chronic migraine
• A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting
  2024-515715-22-00 5 2025-10-06 Episodic migraine
• Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting
  2024-517632-22-00 5 2025-10-06 Hidradenitis Suppurativa
• A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr … Recruiting
  2024-512403-39-01 1 2025-10-03 Advanced Solid Tumors Who Are Beyond Standard of Care
• A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa Recruiting
  2024-519736-17-00 4 2025-10-03 Hidradenitis Suppurativa
• A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting
  2025-521975-30-00 4 2025-10-03 Newly Diagnosed Multiple Myeloma
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• Dose Escalation and Dose Expansion Study of BBO-10203 in Subjects with Advanced Solid Tumors Recruiting
  2024-519445-29-00 1 2025-10-02 Solid Tumors
• A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo … Recruiting
  2025-520499-24-00 5 2025-10-01 Moderate to Severe Platysma Prominence

Showing 913–936 of 3,550 trials